Skip to main content
. Author manuscript; available in PMC: 2010 Mar 1.
Published in final edited form as: Eur J Cancer. 2008 Dec 4;45(4):561–571. doi: 10.1016/j.ejca.2008.10.011

Figure 1.

Figure 1

Toremifene vs. tamoxifen according to disease-free survival (A) and competing risk of second non-breast primary cancer (B) among 1034 postmenopausal patients with node-positive early breast cancer enrolled in IBCSG Trials 12-93 and 14-93. P-value calculated according to Gray (12).